natgillin/translations-raw huggingface dataset:
Patients remained on stable doses of NSAIDs and or prednisone (≤ 0.2 mg /kg/day or 10 mg/day maximum). 
Bolniki so ostali na stabilnih odmerkih nesteroidnih protivnetnih zdravil (NSAIDs - Nonsteroidal Anti-inflammatory drugs) in/ali prednizona (≤ 0,2 mg/kg/dan ali največ 10 mg/dan).
Adalimumab significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard ratio (HR = 0.25 [95% CI: 0.12, 0.49]). 
Adalimumab je značilno zmanjšal tveganje za neuspeh zdravljenja za 75 % glede na placebo, kot prikazuje razmerje ogroţenosti (HR = 0,25 [95 % IZ: 0,12, 0,49]).
Health-related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a pre-specified primary endpoint at week 52 in RA study III. 
Z zdravjem povezano kakovost ţivljenja in telesno funkcijo so v štirih originalnih ustreznih in dobro kontroliranih študijah ocenjevali z indeksom invalidnosti z vprašalnikom HAQ (Health Assessment Questionnaire) in je bila v študiji revmatoidnega artritisa III vnaprej določena primarna končna točka po 52 tednih.
Warning: If the plunger rod is pulled completely out, throw away the syringe. 
Opozorilo: Če je bat popolnoma izvlečen, zavrzite injekcijsko brizgo.
Then administer your child's next dose as you would have on the originally scheduled day, had you not forgotten a dose. 
Nato dajte vašemu otroku naslednji odmerek, kot bi ga uporabili po prvotnem urniku, če ne bi pozabili odmerka.
0.8 mL solution in pre-filled Physioject 
0,8 ml raztopina v napolnjenem Physioject
These results suggest that some patients who have not responded by week 4 benefit from continued maintenance therapy through week 12. 
Ti rezultati nakazujejo, da nekaterim bolnikom, ki se ne odzovejo do 4. tedna, koristi nadaljevanje vzdrţevalnega zdravljenja do 12 tedna.
Warning: Do not use the pre-filled pen if the name on the label is not Kromeya and/or the expiration date on the label has passed. 
Opozorilo: Injekcijske brizge ne uporabljajte, če na injekcijskem peresu ni imena Kromeya in/ali če se je rok uporabnosti iztekel.
The pen is a single use, disposable, handheld, mechanical injection device. 
Peresnik je enoodmerna, enkratna, ročna, mehanska injekcijska naprava.
No clinical data are available on the use of an adalimumab loading dose in children < 6 years of age (see section 5.2). 
Klinični podatki o uporabi polnilnega odmerka adalimumaba pri otrocih, mlajših od 6 let, niso na voljo (glejte poglavje 5.2).
Among patients who had failed prior anti-TNF treatment, week 52 remission was achieved by 3% on placebo and 10% on adalimumab. 
Med bolniki, pri katerih predhodno anti-TNF zdravljenje ni bilo uspešno, jih je 52. teden doseglo remisijo 3 % na placebu in 10 % na adalimumabu.
Patients taking TNF-antagonists are more susceptible to serious infections. 
Bolniki, ki uporabljajo antagoniste tumor nekrotizirajočega faktorja (TNF), so bolj dovzetni za resne okuţbe.
In the open-label extension for RA study III, most patients who were ACR responders maintained response when followed for up to 10 years. 
V odprtem podaljšanju študije revmatoidnega artritisa III se je večina bolnikov, ki so se odzvali po ACR, odzivala še naprej v času sledenja do 10 let.
Description of selected adverse reactions 
Opis izbranih neţelenih učinkov
These therapies include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and/or gold salts. 
Zdravljenja so vključevale metotreksat, leflunomid, hidroksiklorokin, sulfasalazin in/ali soli zlata.
Standard dose 
Standardni odmerek
Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors, ATC code: L04AB04 
Farmakoterapevtska skupina: zdravila za zaviranje imunske odzivnosti, zaviralci tumor nekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB04
diverticulitis 
divertikulitis
In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening. 
V redkih primerih, zlasti če uporabljate druga zdravila, ki zavirajo imunski sistem, je reaktivacija HBV okuţbe lahko smrtno nevarna.
MTX = methotrexate **p < 0.01, adalimumab versus placebo 
MTX = metotreksat **p < 0,01, adalimumaba v prim.
Some of those patients were also treated with the medicines azathioprine or mercaptopurine. 
Nekateri od teh bolnikov so bili zdravljeni tudi z zdravilom azatioprinom ali merkaptopurinom.
Cases of worsening congestive heart failure have also been reported in patients receiving adalimumab. 
O primerih poslabšanja kongestivnega srčnega popuščanja so poročali tudi pri bolnikih, ki so prejemali adalimumab.
The safety and efficacy of adalimumab was assessed in two studies (pJIA I and II) in children with active polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types (most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis). 
Varnost in učinkovitost adalimumaba so ocenili v dveh študijah (pJIA I in II) pri otrocih z aktivnim poliartikularnim ali poliartikularnim juvenilnim idiopatskim artritisom, z različnimi tipi začetka JIA (najpogosteje negativen revmatoidni faktor ali pozitiven poliartritis in razširjen oligoartritis).
• lupus-like syndrome; 
• sindrom podoben lupusu;
• Do not use the Kromeya pre-filled syringe if it has been dropped or crushed, as the pre-filled syringe may be broken even if you cannot see the break. 
• Zdravila Kromeya napolnjena injekcijska brizga ne uporabljajte, če vam je padlo iz rok ali je bila brizga strta, saj je lahko injekcijska brizga poškodovana, tudi če ne vidite razpok.
Your doctor will decide if your child should receive Kromeya. 
On se bo odločil, ali lahko vaš otrok dobiva zdravilo Kromeya.
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data). 
Naslednji seznam neţelenih učinkov je osnovan na izkušnjah iz kliničnih preskušanj in iz obdobja trţenja zdravila in jih razvršča po organskih sistemih in pogostnosti v preglednici 6, spodaj: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000) in neznana pogostnost (pogostnosti iz razpoloţljivih podatkov ni mogoče oceniti) (<1/10.000).
1.4 Check the expiration date on the side of the box (Figure C). 
1.4 Preverite rok uporabnosti, ki je odtisnjen na strani škatle (Slika C).
Week 24 ***,** Statistically significant at p < 0.001, < 0.01 for all comparisons between adalimumab and placebo at weeks 2, 12 and 24 
24. teden ***,** Statistično značilno pri p < 0,001, < 0,01 za vse primerjave med adalimumabom in placebom po 2, 12 in 24 tednih a
Adalimumab has not been studied in patients with enthesitis-related arthritis aged less than 6 years. 
Adalimumab niso preučevali pri bolnikih z artritisom, povezanim z entezitisom, starih manj kot 6 let.
• Can be closed with a tight-fitting, puncture-resistant lid; that will keep sharps from coming out, 
• se lahko zapre s tesno prilegajočim pokrovom, ki ga ni mogoče prebosti; tako ostri predmeti ne bodo mogli pasti iz koša,
These infections have not consistently been recognised in patients taking TNFantagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. 
Takšne okuţbe se pri uporabnikih antagonistov TNF niso prepoznale vedno, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
RA study III also had a primary endpoint of changes in quality of life. 
Študija revmatoidnega artritisa III je imela kot primarno končno točko tudi spremembe v kakovosti ţivljenja.
People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting lymphoma and leukaemia (cancers that affect blood cells and bone marrow). 
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen ţe dolgo, obstaja povečana verjetnost, da zbolijo za limfomom in levkemijo (vrsto raka, ki prizadene krvne celice in kostni mozeg).
Kromeya is used to treat: 
Zdravilo Kromeya se uporablja za zdravljenje:
Improvement in quality of life was measured up to week 156 (36 months) and improvement was maintained through that time. 
Do 156. tedna (36. meseca) se je ocenjevalo izboljšanje kvalitete ţivljenja, ki se je v tem času tudi ohranilo.
With the current knowledge, a possible risk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be excluded. 
S sedanjim znanjem moţnega tveganja za razvoj limfomov, levkemije in drugih malignomov pri bolnikih, zdravljenih z antagonistom TNF, ni mogoče izključiti.
Taking these results into consideration, Kromeya is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2). 
Z upoštevanjem teh ugotovitev je zdravilo Kromeya priporočljivo uporabljati v kombinaciji z metotreksatom, kot monoterapijo pa pri bolnikih, za katere uporaba metotreksata ni primerna (glejte poglavje 4.2).
If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Kromeya, and in accordance with local recommendations. 
Če ugotovite latentno tuberkulozo, morate pred uvedbo zdravila Kromeya začeti z ustreznim protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
• With your other hand gently pinch skin (without squeezing) to avoid injecting into a muscle 
• Z drugo roko neţno stisnite koţo (brez stiskanja), da bi preprečili injiciranje v mišico (Slika O).
• an alcohol pad (included in the box) 
• zloţenec, navlaţen z alkoholom (priloţen v škatli),
Adalimumab Δ Censored 
Adalimumab Δ anonimizirano
Patients treated with Kromeya should be given the patient reminder card. 
Bolniki, ki se zdravijo z zdravilom Kromeya, morajo dobiti posebno opozorilno kartico za bolnike.
• Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV infection or if you think you might be at risk of contracting HBV. 
• Zdravniku morate povedati, če ste nosilec virusa hepatitisa B (HBV), če imate aktivno HBV okuţbo ali če mislite, da bi se lahko nalezli HBV.
Treatment failure was defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual acuity (BCVA). 
Neuspeh zdravljenja je bil definiran z večkomponentnim izidom, ki je temeljil na vnetnih horioretinalnih in/ali vnetnih retinalnih vaskularnih lezijah, oceni celic sprednje očesne komore, motnosti steklovine in najboljši korigirani ostrini vida (BCVA - best corrected visual acuity).
(Figure O). 
(Slika O).
• Push the injection button (Figure P). 
• Pritisnite na gumb za injiciranje (Slika P).
In some rare cases, especially if your child is taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening. 
V redkih primerih, zlasti če vaš otrok uporablja druga zdravila, ki zavirajo imunski sistem, je reaktivacija HBV lahko smrtno nevarna.
1.5 Check your records for injection dates and injection sites to figure out the injection site for this session. 
1.5 Preverite datume in mesta injiciranja, ki ste si jih zabeleţili, da boste lahko določili mesto za naslednje injiciranje.
Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). 
Bolniki, ki so dobivali adalimumab, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) v obeh vprašalnikih, SF36 in ASQoL (Vprašalnik o kakovosti ţivljenja pri ankilozirajočem spondilitisu - Ankylosing Spondylitis Quality of Life Questionnaire).
1.5 Take a pre-filled pen out of the original box: 
1.5 Napolnjen injekcijski peresnik vzemite iz originalne ovojnine:
Warning: Do not touch where you aim to inject. 
Opozorilo: Ne dotikajte se mesta, kamor nameravati injicirati zdravilo.
After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period B and received open-label 40 mg adalimumab every other week. 
Po 16 tednih zdravljenja so bolniki, ki so dosegli odziv PASI vsaj 75 (izboljšanje ocene PASI za vsaj 75 % glede na izhodišče), vstopili v obdobje B, med katerim so odprto dobivali 40 mg adalimumaba vsak drugi teden.
Maintenance of clinical remission was evaluated in CD study III (CHARM). 
Vzdrţevanje klinične remisije so ovrednotili v študiji Crohnove bolezni III (CHARM).
Step 2 Prepare Vial 
2. korak Pripravite vialo
▪ the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. 
• Zdravljenje hudega, aktivnega in progresivnega revmatoidnega artritisa pri odraslih, ki prej še niso bili zdravljeni z metotreksatom.
Maintenance dose starting at week 4 
Vzdrţevalni odmerek bolnika z začetkom v 4. tednu
Psoriasis is believed to be caused by a problem with the body's immune system that leads to an increased production of skin cells. 
Domneva se, da luskavico povzroči motnja v delovanju imunskega sistema, ki ima za posledico povečano nastajanje koţnih celic.
After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical response per PCDAI. 
Po 5 letih zdravljenja z adalimumabom se je glede na PCDAI klinična remisija nadaljevala pri 74,0 % (37/50) od 50 bolnikov, ki so ostali v študiji, klinični odziv pa se je nadaljeval pri 92,0 % (46/50) bolnikov, ki so ostali v študiji.
• In some patients the body may fail to produce enough of the blood cells that fight off infections or help you to stop bleeding. 
• Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki premagujejo okuţbe ali pomagajo zaustaviti krvavitve.
• Tell your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections. 
• Zdravniku povejte, če ste imeli v preteklosti ponavljajoče se okuţbe ali druge bolezni, ki zvečujejo tveganje za okuţbe.
• heart problems that can cause shortness of breath or ankle swelling; 
• teţave s srcem, ki lahko povzročijo kratko sapo ali otekanje gleţnjev;
Kromeya can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment. 
Zdravilo Kromeya je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
5.1 Choose an injection site on: 
5.1 Izberite mesto injiciranja na:
• neurological infections (including viral meningitis); 
• nevrološke okuţbe (vključno z virusnim meningitisom);
The primary efficacy endpoint was the proportion of patients with no flare by week 68 of the study. 
Primarni opazovani dogodek kot merilo učinkovitosti je bil deleţ bolnikov brez ponovnega zagona bolezni do 68. tedna študije.
Patients induced with 160/80 mg adalimumab achieved clinical remission versus placebo at week 8 in statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study UC-II (17% vs. 9% respectively, p=0.019). 
Bolniki, ki so za indukcijo dobili 160/80 mg adalimumaba, so 8. teden v primerjavi s placebom dosegli klinično remisijo v statistično značilno večjem odstotku tako v študiji UC-I (18 % v primerjavi z 9 %, p = 0,031) kot v študiji UC-II (17 % v primerjavi z 9 %, p = 0,019).
Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients (paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn's disease, and enthesitis-related arthritis). 
Izpostavljenost adalimumabu pri pediatričnih bolnikih z uveitisom je bila napovedana z uporabo populacijskega farmakokinetičnega modeliranja in simulacije, ki temelji na farmakokinetiki navzkriţnih indikacij pri drugih pediatričnih bolnikih (psoriaza pri pediatričnih bolnikih, juvenilni idiopatski artritis, Crohnova bolezen pri pediatričnih bolnikih in artritis, povezan z entezitisom) .
It is very important that you tell your doctor if your child has ever had tuberculosis, or if he/she has been in close contact with someone who has had tuberculosis. 
Zelo pomembno je, da zdravniku poveste, če je vaš otrok kadarkoli imel tuberkulozo ali je bil v tesnem stiku s kom, ki jo je imel.
Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), including adalimumab in the post marketing setting. 
Med obdobjem trţenja so bili opisani malignomi (nekateri s smrtnim izidom) pri otrocih, mladostnikih in mladih odraslih (starih do 22 let), ki so dobivali antagoniste TNF, vključno z adalimumabom (začetek zdravljenja v starosti ≤ 18 let).
20 mg every other week in combination with methotrexate 
20 mg vsak drugi teden v kombinaciji z metotreksatom
If you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
ASAS partial remission BASDAI 
ASAS delno izboljšanje BASDAI
In study UV I statistically significant differences in favour of adalimumab versus placebo were observed for each component of treatment failure. 
V študiji UV I so opazili statistično pomembne razlike v korist adalimumaba v primerjavi s placebom za vsako od komponent neuspeha zdravljenja.
6.5 Center your thumb or forefinger on the textured finger pad and push the safety cover forward over the needle until you hear or feel it locks. 
6.5 Palec poloţite na ustrezno reliefno mesto in potisnite varovalo naprej čez injekcijsko iglo, dokler ne slišite ali vidite, da je pravilno nameščeno.
Always take the outer carton of the medicine with you, even if it is empty. 
Vedno vzemite s seboj zunanjo ovojnino zdravila, tudi če je prazna.
At week 12 and week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed data approach. 
12. teden je bil odziv PedACR30 93,5 % in 24. teden 90,0 % (z uporabo pristopa z opaţenimi podatki).
Mood alterations (including depression), anxiety, insomnia 
Psihiatrične motnje pogosti spremembe razpoloţenja (vključno z depresijo), anksioznost, nespečnost
Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with Kromeya. 
Bolnike je zato treba pred, med in po zdravljenju z zdravilom Kromeya natančno kontrolirati glede okuţb, vključno s tuberkulozo.
Adults with rheumatoid arthritis 
Odrasli z revmatoidnim artritisom
Kromeya can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs). 
Zdravilo Kromeya se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), kortikosteroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
• Vaccinations: if possible children should be up to date with all vaccinations before using Kromeya. 
• Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Kromeya opravi vsa potrebna cepljenja.
• WATCH the syringe plunger to make sure it moves all the way down to the bottom (Figure P). 
• OPAZUJTE bat, da se prepričate, ali se je pomaknil do konca (Slika P).
• Give plunger a final push to ensure the full dose has been injected (Figure R). 
• Bat potisnite še enkrat, da se prepričate, ali ste injicirali celoten odmerek (Slika R).
The decision to stop using Kromeya should be discussed with your doctor. 
O odločitvi, da bi prenehali uporabljati zdravilo Kromeya, se morate posvetovati s svojim zdravnikom.
Warning: If you have psoriasis, do not inject into any lesions or red, thick, raised or scaly patches. 
Opozorilo: Če imate psoriazo, zdravila ne injicirajte v lezije ali v predele, ki so pordeli, odebeljeni, privzdignjeni ali se luščijo.
4.1 Choose an injection site (Figure J) on: 
4.1 Izberite mesto injiciranja (Slika J) na:
After proper training in injection technique, patients may self-inject with Kromeya if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Kromeya lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
• pleural effusion (abnormal collection of fluid in the pleural space); 
• plevralna efuzija (nenormalno nabiranje tekočine v plevralnem prostoru);
Patients who develop a new infection while undergoing treatment with Kromeya, should be monitored closely and undergo a complete diagnostic evaluation. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Kromeya pojavi nova okuţba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
Improvement in number of active joints with arthritis was maintained during the OL period through week 156 for the 26 of 31 (84%) patients in the adalimumab group who remained in the study. 
Izboljšanje v številu aktivnih sklepov z artritisom se je ohranilo v obdobju odprtega preskušanja po 156. tednu pri 26 od 31 (84 %) bolnikov, ki so ostali v študiji in ki so prejemali adalimumab.
During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm. 
V 52 tednih študij UC-I in UC-II so opazili niţjo stopnjo hospitalizacije iz vseh razlogov in hospitalizacije, povezane z ulceroznim kolitisom, pri skupini, zdravljeni z adalimumabom, v primerjavi s placebo skupino.
Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralizing antibodies in rodents. 
Z adalimumabom niso bile narejene niti raziskave kancerogenosti, niti standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkriţno reaktivnostjo z glodalskim TNF, in zaradi nastanka nevtralizirajočih protiteles pri glodalcih.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 19. 
Stopnja prenehanja zdravljenja s kortikosteroidi ali imunomodulatorji je predstavljena v preglednici 19.
Consequently, Kromeya can be used during breast-feeding. 
Posledično se zdravilo Kromeya lahko uporablja med dojenjem.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 18. 
Stopnja klinične remisije in kliničnega odziva (definiran kot zmanjšanje vrednosti PCDAI vsaj za 15 točk od začetne vrednosti) sta predstavljena v preglednici 18.
These include: 
Ena škatla vsebuje:
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 24. 
Stopnja klinične remisije in kliničnega odziva (definiran kot zmanjšanje vrednosti PCDAI vsaj za 15 točk od začetne vrednosti) sta predstavljena v preglednici 24.